Iradimed Corp Dossier
Qualitative Analysis
Business overview
IRADIMED CORP (NASDAQ: IRMD) is a global leader in the development, manufacture, marketing, and distribution of innovative Magnetic Resonance Imaging (MRI) compatible medical devices. The company is uniquely positioned as the sole provider of non-magnetic intravenous (IV) infusion pump systems designed specifically for safe use within the harsh magnetic fields of MRI environments. Its primary product lines include the MRidium MRI-compatible IV infusion pump systems and the 3880 MRI-compatible patient vital signs monitoring systems. These specialized devices ensure patient safety and continuous drug delivery or monitoring during imaging procedures, serving hospitals, acute care facilities, and outpatient imaging centers globally, with the majority of revenue generated in the United States.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Executing the full commercial launch and replacement cycle of legacy 3860 MRI-compatible infusion pump systems with the next-generation 3870 platform. The initiative targets a $50 million annual revenue run rate for pumps domestically by selling over 2,000 channels annually at a higher average selling price (ASP).
Expected impact: Serves as the primary top-line growth driver, supporting the company's target of achieving a $100 million-plus annual revenue run rate during 2026.
Investing in research and development to design and launch a next-generation, updated MRI-compatible patient vital signs monitor to succeed the current 3880 system.
Expected impact: Maintains technological leadership in the specialized MRI patient monitoring niche and expands the long-term addressable market.
Navigating regulatory pathways to secure CE Mark approval in Europe and PMDA clearance in Japan for the MRidium 3870 pump system, alongside expanding international distribution partnerships.
Expected impact: Diversifies revenue streams geographically and reduces concentration risk in the domestic US market.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations